KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Equivalents (2016 - 2025)

Nektar Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $15.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $15.1 million for Q4 2025, down 65.84% from a year ago — trailing twelve months through Dec 2025 was $15.1 million (down 65.84% YoY), and the annual figure for FY2025 was $15.1 million, down 65.84%.
  • Cash & Equivalents for Q4 2025 was $15.1 million at Nektar Therapeutics, down from $41.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NKTR hit a ceiling of $152.3 million in Q2 2021 and a floor of $15.1 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $49.7 million (2023), compared with a mean of $61.9 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 87.32% in 2021 and later soared 249.86% in 2022.
  • Nektar Therapeutics' Cash & Equivalents stood at $25.2 million in 2021, then soared by 249.86% to $88.2 million in 2022, then tumbled by 60.02% to $35.3 million in 2023, then rose by 25.44% to $44.3 million in 2024, then plummeted by 65.84% to $15.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $15.1 million (Q4 2025), $41.0 million (Q3 2025), and $43.0 million (Q2 2025) per Business Quant data.